Clinical Trial On Mildly Symptomatic Covid -19 Patients And Health Care Workers Posted To Covid Wards

A Prospective, Open Label, Three Arm, Single Center, Controlled Study To Assess The Immune-Boosting Activity Of Mulmina Mango And Mulmina Amla Orange Health Drink in Asymptomatic, mildly Symptomatic COVID-19 patients and health care workers posted to COVID w

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025702

Enrollment

120

Registered

2020-06-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: A.MulminaTM Mango: It is a immunoboosting drink : Dose: 200ml Dosage form: Oral Drink Frequency : 2 times daily Route of administrate : Orally Total duration: 28 days Intervention2

Eligibility

Inclusion criteria

Inclusion criteria: 1.Volunteer aged between 18-60 years (both inclusive) 2.Clinical evidence of COVID-19 and Asymptomatic Mildly Symptomatic Covid -19 patients. 3.Health Care Workers Posted to Covid Wards.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or breast feeding. 2.Patients with preexisting severe systemic disease necessitating longterm medication. 3.Evidence of significant uncontrolled comorbid disease, like diabetes Type I or II, which in the investigators opinion would jeopardize patient participation. 4.History of cancer, including solid tumours, hematologic malignancies and carcinoma in situ. 5. Any neurological congenital or acquired, vascular or systemic disorder which could affect any of the efficacy assessments. 6. Participation in the current or previous treatment with any approved or investigational health supplements during the past 1 month.

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of A & B health drinks as supplement in COVID-19 patients Serum Immuno biomarkers: Serum amyloid A â?? SAA, IL-4, IL-6, IFN-gamma, CRP,Lymphocyte Count-L & IgA Serum Antioxidant Markers: Superoxide dismutase (SOD),Catalase (CAT),Malondialdehyde (MDA),Glutathione (GSH) Timepoint: Day 0 to Day 28	—

Secondary

Measure	Time frame
â?¢ To assess the organoleptic properties of A & B health drinks through a feedback questionnaireTimepoint: Day 0 to Day 28	—

Countries

India

Contacts

Public ContactMr Raghavendra K V

Radiant Research Services Pvt. Ltd

ashok@radiantresearch.in9880999297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026